ImmunityBio (IBRX) EBITDA Margin (QoQ) (2014 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) EBITDA Margin (QoQ) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.10 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,747.00 |
| Mar 31, 2026 | 1,107.00 |
| Dec 31, 2025 | 456.00 |
| Sep 30, 2025 | 9,625.00 |
| Jun 30, 2025 | 12,031.00 |
| Mar 31, 2025 | 52,888.00 |
| Dec 31, 2024 | 39,537.00 |
| Sep 30, 2024 | 817,306.00 |
| Jun 30, 2024 | 22.85 Mn |
| Mar 31, 2024 | -17.66 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 10.99 Mn |
| Jun 30, 2023 | -17.67 Mn |
| Mar 31, 2023 | 8.53 Mn |
| Dec 31, 2022 | -3.93 Mn |
| Sep 30, 2022 | 15.05 Mn |
| Jun 30, 2022 | 45.80 Mn |
| Mar 31, 2022 | -66.52 Mn |
| Dec 31, 2021 | 9.91 Mn |
| Sep 30, 2021 | -9.41 Mn |